Mineralys Therapeutics to release results of trials for hypertension treatment lorundrostat on March 10

From GlobeNewswire: 2025-03-07 16:01:00

Mineralys Therapeutics will announce topline results from its Launch-HTN and Advance-HTN trials on March 10th at 8:00 a.m. ET. The Launch-HTN trial studied lorundrostat as an add-on therapy for uncontrolled or resistant hypertension, while the Advance-HTN trial focused on lorundrostat as an add-on therapy to existing treatments. The company is developing lorundrostat, a highly selective aldosterone inhibitor, for conditions like hypertension, chronic kidney disease, and obstructive sleep apnea. For more information, visit Mineralys Therapeutics’ website or follow them on social media. Contact investor relations at [email protected] for inquiries.



Read more at GlobeNewswire: Mineralys Therapeutics to Announce Topline Data from